Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis

Journal of Tissue Engineering and Regenerative Medicine

Volumn 4, Issue 5, 2006, Pages 1086-1094

  Diamandis, M ^a   Adam, F ^a   Kahr, W H A ^a   Wang, P ^a   Chorneyko, K A ^a   Arsenault, A L ^a   Rivard, G E ^b   Hayward, C P M ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Congenital bleeding disorders; Fibrinolysis; Plasmin; Platelet disorders; Urokinase type plasminogen activator

Indexed keywords

BLEEDING DISORDER; BLEEDINGS; CONGENITAL BLEEDING DISORDER; FIBRINOLYSE; PLASMIN; PLASMINOGEN ACTIVATORS; PLATELET DISORDER; UROKINASE-TYPE PLASMINOGEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; WHOLE BLOOD;

PLATELETS;

ARTICLE; CANADA; CELL ADHESION; ELECTRON MICROSCOPY; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; THROMBOCYTE; THROMBOCYTE DISORDER;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CELL ADHESION; HUMANS; MICROSCOPY, ELECTRON; QUEBEC;

EID: 84878046464     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01877.x     Document Type: Article

References (44)

1. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243-52.
2. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005; 3: 1773-82.
3. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1: 1628-36.
4. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 2005; 257: 209-23.
5. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31: 381-92.
6. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001.
7. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-33.
8. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-5.
9. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104: 3943-8.
10. Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74: 1221-8.
11. Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87: 4967-78.
12. McKay H, Derome F, Haq MA, Whittaker S, Arnold E, Adam F, Heddle NM, Rivard GE, Hayward CP. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104: 159-65.
13. Hayward CP, Cramer EM, Kane WH, Zheng S, Bouchard M, Massé JM, Rivard GE. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granulemembrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89: 1243-53.
14. Janeway CM, Rivard GE, Tracy PB, Mann KG. Factor V Quebec revisited. Blood 1996; 87: 3571-8.
15. Hayward CP, Welch B, Bouchard M, Zheng S, Rivard GE. Fibrinogen degradation products in patients with the Quebec platelet disorder. Br J Haematol 1997; 97: 497-503.
16. Kahr WH, Zheng S, Sheth PM, Pai M, Cowie A, Bouchard M, Podor TJ, Rivard GE, Hayward CP. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinasetype plasminogen activator. Blood 2001; 98: 257-65.
17. Sheth PM, Kahr WH, Haq MA, Veljkovic DK, Rivard GE, Hayward CP. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost 2003; 90: 293-8.
18. Hayward C. Inherited disorders of platelet alpha-granules. Platelets 1997; 8: 197-210.
19. Tubman VN, Levine JE, Campagna DR, Fleming MD, Neufeld EJ. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation [abstract]. Blood 2005; 106: 5.
20. Kufrin D, Eslin DE, Bdeir K, Murciano JC, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 926-33.
21. Bettex-Galland M. Clot Retraction. In: Bang NU, Beller FK, Deutsch E, Mammen EF, eds. Thrombosis and Bleeding Disorders. New York, NY: Academic Press Inc., 1971: 441-5.
22. RivardGE, Brummel-ZiedinsKE, Mann KG, FanL, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-43.
23. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
24. Adam F, Zheng S, Joshi N, Delton DS, Sandhu A, Suehiro Y, Jeimy SB, Santos AV, Massé JM, Kelton JG, Cramer EM, Hayward CP. Analyses of cellularmultimerin 1 receptors: in vitro evidence of binding mediated by aIIbb3 and avb3. Thromb Haemost 2005; 94: 1004-11.
25. EnglundGD, Bodnar RJ, Li Z, Ruggeri ZM, Du X. Regulation of von Willebrand factor binding to the platelet glycoprotein Ib-IX by a membrane skeleton-dependent inside-out signal. J Biol Chem 2001; 276: 16952-9.
26. Braaten JV, Jerome WG, Hantgan RR. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface. Blood 1994; 83: 982-93.
27. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-9.
28. Hamaguchi M, Bunce LA, Sporn LA, Francis CW. Plasmic degradation of fibrin rapidly decreases platelet adhesion and spreading. Blood 1994; 84: 1143-50.
29. Veklich Y, Francis CW, White J, Weisel JW. Structural studies of fibrinolysis by electron microscopy. Blood 1998; 92: 4721-9.
30. Weisel JW, Veklich Y, Collet JP, Francis CW. Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999; 82: 277-82.
31. Meh DA, Mosesson MW, DiOrio JP, Siebenlist KR, Hernandez I, Amrani DL, Stojanovich L. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coagul Fibrinolysis 2001; 12: 627-37.
32. Huang TC, Jordan RE, Hantgan RR, Alevriadou BR. Differential effects of c7E3 Fab on thrombus formation and rt-PA-mediated thrombolysis under flow conditions. Thromb Res 2001; 102: 411-25.
33. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990; 76: 345-53.
34. Kuijpers MJ, Nieuwenhuys CM, Feijge MA, Kloots W, Giesen PL, Jerling JC, oude Egbrink MG, Heemskerk JW. Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood. Thromb Haemost 2005; 93: 97-105.
35. Kuijper PH, Gallardo Torres HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood 1997; 89: 166-75.
36. Granelli-Piperno A, Vassalli JD, Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J ExpMed 1977; 146: 1693-706.
37. Heiple JM, Ossowski L. Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. J ExpMed 1986; 164: 826-40.
38. Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001; 113: 72-80.
39. Moir E, Robbie LA, Bennett B, Booth NA. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost 2002; 87: 1006-10.
40. Moir E, Greaves M, Adey GD, Bennett B. Polymorphonuclear leukocytes from patients with severe sepsis have lost the ability to degrade fibrin via u-PA. J Leukoc Biol 2004; 76: 571-6.
41. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost 2003; 89: 610-21.
42. Nagamine Y, Medcalf RL, Munoz-Canoves P. Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 2005; 93: 661-75.
43. Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest 1973; 52: 1647-59.
44. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004; 279: 18 434-9.